Yahoo News , July 12th, 2010Research into Alzheimer’s disease has reached a point of significant potential, even as the disease’s looming impact on society grows more and more dire, experts say. Some leading scientists, in fact,

Read more here:
NewRetirement Retirement News Digest : Experts Optimistic About …

As a family foundation, we get a whole lot of deal flow (a phrase I’ve learned from my friends in the investment community) – in other words we see scores of incredible (and some times not so incredible) grant proposals and social … Malaria No More works to raise the profile of the disease among the public, policymakers, and businesses , while engaging the private sector to provide life-saving mosquito nets and other critical interventions to families in Africa. …

Here is the original post:
Great nonprofits that should make your holiday list

When it comes to Alzheimer’s disease, the good news is that the last few decades have seen an explosion in fundamental scientific knowledge about what causes Alzheimer’s and what happens as the disease progresses. … Diabetes can affect many people in independent living communities and other retirement communities, since approximately half of all diabetes cases are diagnosed in people aged 60 or older, according to the Centers for Disease Control and Prevention. …

See more here:
The Outlook for Alzheimer's

Creative Real Estate Investing . tips on flipping real estate with no down payment, creative short sales and more! home · archives · about. ← Why is it Important to Stop Gum Disease? Taking care of older cars → …

Go here to read the rest:
Bathroom remodeling and the things that one needs to upgrade …

GlaxoSmithKline ( GSK ) received positive news yesterday when the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of the company’s experimental kidney cancer drug, Votrient (pazopanib). Importantly, the panel voted that Votrient can benefit patients by slowing the disease, despite some risk of liver damage. We believe the company may be asked to submit data from ongoing studies to ensure that liver toxicity associated with the use o

Read more:
FDA Panel Backs Glaxo’s Votrient – Analyst Blog